MedTrace Logo

Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer

NCT07648745 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-15

No results posted yet for this study

Summary

Ovarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal. This trial is testing whether a drug called cediranib can be used safely together with paclitaxel chemotherapy to treat ovarian cancer in women at risk of bowel obstructions. All participants will receive the cediranib/paclitaxel combination, and if the cancer worsens the participant will stop receiving paclitaxel and may receive an additional drug, olaparib, together with cediranib.

Conditions

Interventions

DRUG

Cediranib

Cediranib in combination with weekly paclitaxel

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Cardiff University

    collaborator OTHER

  • Prof Gordon Jayson

    lead OTHER

Principal Investigators

  • Andrew Clamp · The Christie NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-14
Primary Completion
2025-01-14
Completion
2025-01-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07648745 on ClinicalTrials.gov